På denne side bringer DANSK BIOTEK nyheder fra medlemmerne, som på denne måde får mulighed for at blive ekstra eksponeret.

Vi modtager derfor gerne pressemeddelelser og andre nyheder. Send dem til Dorte Dannemann, hjælp af denne formular.

04 Feb 2015

European Biotechnology. “IPO windfall for Ascendis”

European Biotechnology wrote that although the European stock markets are registering a boom, some biotechs still feel safer in the tried-and-tested US waters. Danish clinical stage biopharma company Ascendis Pharma has successfully raised US$108m (€95.5) by offering 6 million shares at US$18 (€16m). The Copenhagen-based company can be pleased with the result – initially they had offered only 5 million shares, with a price range of US$16 to US$18. Ascendis will trade under the ticker symbol “ASND.”
Meanwhile, Irish biotech Nexvet has announced the terms for its own IPO on the other side of the Atlantic. The Dublin-based clinical-stage biopharmaceutical company develops therapeutic monoclonal antibodies for pets. Nexvet also plans to list on NASDAQ and wants to raise US$58m (€51m), with each of the 4 million shares offered for US$13 to US$16 (€11.5 to €14.1).
Continuing the recent rush of European stock markets listings, Liverpool-based Redx Pharma announced this week it would be staying this side of the pond for its €105m initial public offering: the drug developer aims to float on the London Stock Exchange AIM.

If you can't find it here or have feedback to our website, please do not hesitate to contact dd@danskbiotek.dk or +45 5150 0560

Copyright 2015 Danskbiotek. All rights reserved.